It is necessary to further clarify the expression of SEMA4D and its inhibitory function in immune cell subsets within the tumor microenvironment using single-cell sequencing technology in order to identify the targets and mechanisms of anti-SEMA4D immunotherapy, and ultimately achieve the goal of promoting the therapeutic effect of combination immunotherapy with ICI. Here, SEMA4D is linked to neoplasm.